Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance

NCT ID
NCT07759336
Registry status
Not yet recruiting
Study type
Interventional
Phase
Phase 4
Sponsor
Benedict Alter
Conditions
Chronic Knee Pain, Chronic Pain, Knee Osteoarthritis (Knee OA)

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Enrollment: 85 participants (Estimated).

What is being studied

  • Drug: Duloxetine
  • Intervention: Duloxetine Hydrochloride
  • Intervention: Heterocyclic Compounds
  • Intervention: Heterocyclic Compounds, 1-Ring
  • Intervention: Organic Chemicals
  • Drug: Placebo
  • Intervention: Sulfur Compounds
  • Intervention: Thiophenes

Who may be eligible

Ages
45 Years to 80 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Knee pain for greater than 6 months. * Moderate-to-severe knee pain (\>3/10) due to osteoarthritis, as defined by American College of Rheumatology and EULAR diagnostic criteria (Zhang 2010, Altman 1986) on \>50% of days in the past month. * KL grade 2-4 (Kellgren and Lawrence 1957) indicating significant degenerative changes on knee X-ray. This will be determined on evaluation of weight-bearing clinical X-rays on review of medical records. In the infrequent situation that the patient does not have an X-ray on review of their medical records, then the patient will obtain weight-bearing knee X-rays as part of the Screening Visit. * Age: 45-80 years old * Gender: Males and females will be recruited. * Language: only English-speaking subjects will be included. Exclusion Criteria: * Inflammatory arthritis (e.g. rheumatoid arthritis). * More intense pain due to another chronic pain syndrome (e.g. fibromyalgia, hip osteoarthritis) * Significant pain or weakness in the lower extremities due to a neurological condition (e.g. lumbar radiculopathy, paresis due to stroke) * New, ongoing acute pain * Recent use of duloxetine defined as any use within the last 3 months * Current use of antidepressants or tramadol * Current routine use of more than 30 mg oral morphine equivalents per day (use of \<=30 mg OME does not exclude the participant). * New treatment that may help knee osteoarthritis (including medication, exercise, behavioral, or complementary and integrative treatments) started in the last month. Stable use of treatments for greater than 1 month does not exclude the participant. * Unwillingness to maintain current knee osteoarthritis treatments for the duration of the study. This means that eligible participants must plan for the following: medications and dietary supplements should not change substantially in frequency or dose; behavioral therapy, exercise therapy, and complementary and integrative therapies should be consistent; and there should be no interventional treatments planned for lower extremity musculoskeletal conditions (e.g. joint steroid injections, knee radiofrequency ablation, knee replacement surgery). * Recent knee intra-articular injection of steroid or other agent (greater than 1 month does not exclude the participant) * Recent knee radiofrequency ablation (greater than 3 months does not exclude the participant) * Recent knee arthroscopic surgery (greater than 3 months does not exclude the participant) * History of knee replacement or open knee surgery on the index knee, defined as the more painful knee on average over the last month. * Inability to walk or climb stairs without significant assistance (e.g. a one-person assist, use a wheelchair; use of a cane does not exclude the participant). * Inability to participate in study procedures (e.g. cognitive impairment limiting ability to understand directions, inability to understand and read English) * Uncontrolled or unstable medical disorder preventing participation in study procedures * History of brain surgery * Tattoos on sensory testing sites * Pregnancy * History of severe renal impairment defined by GFR \< 30 ml/min or, if renal function testing is not available on EMR review, patient-reported history of acute or chronic kidney disease of any severity * History of chronic liver disease or cirrhosis * History of angle-closure glaucoma

Study locations

1 study location is listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: United States

  • Pennsylvania, United States: 1

Sample of listed locations

  • University of Pittsburgh - Center for Innovation in Pain Care (Research) — Pittsburgh, Pennsylvania, 15206, United States — Site recruitment status not specified in the registry data

Study details

Start date
August 1, 2026
Primary completion date
August 1, 2028
Completion date
August 1, 2028
First posted
August 12, 2026
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07759336
Registry last updated
August 12, 2026
QualifiedStudies registry data refreshed
October 2, 2026
QualifiedStudies record fetched
October 2, 2026

View NCT07759336 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Clinical trial FAQ